(Q34397294)

1 August 2017

Substantial rise in sparteine metabolic ratio during haloperidol treatment (English)

1 reference

1 August 2017

1 reference

Gram LF

1

1 reference

1 August 2017

Debruyne D

2

1 reference

1 August 2017

Caillard V

3

1 reference

1 August 2017

Boulenger JP

4

1 reference

1 August 2017

Lacotte J

5

1 reference

1 August 2017

Moulin M

6

1 reference

1 August 2017

Zarifian E

7

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 February 1989

1 reference

British Journal of Clinical Pharmacology

1 August 2017

1 reference

1 August 2017

27

1 reference

1 August 2017

272-275

1 reference

1 August 2017

2

1 reference

Sparteine metabolism in Canadian Caucasians

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379791

Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379791

Sparteine oxidation is practically abolished in quinidine-treated patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379791

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379791

Inhibitory effects of neuroleptics on debrisoquine oxidation in man

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1379791

Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1989.TB05362.X

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1989.TB05362.X

A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients

21 January 2018

1 reference

12 December 2020

In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver

1 reference

12 December 2020

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

12 December 2020

Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients

1 reference

12 December 2020

Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs

1 reference

12 December 2020

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

1 reference

12 December 2020

Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics

1 reference

12 December 2020

Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype

1 reference

12 December 2020

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

1 reference

12 December 2020

Effects of perphenazine on imipramine metabolism in man

1 reference

12 December 2020

10.1111/J.1365-2125.1989.TB05362.X

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference